For TGAs, we identified 43 genes, including those that are currently under clinical investigation as ACT targets such as NY-ESO-1 (CTAG1A) in synovial sarcoma (D’Angelo et al., 2018b), and PRAME in a number of histologic types (Gutzmer et al., 2016; Luk et al., 2018) (Figure 4C; Table S3C). Here, CTAG1A is linked to synovial sarcoma.